Genetically Modified RPE Cells for Retinal Degeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for retinal degeneration and related visual disorders, such as age-related macular degeneration and retinitis pigmentosa, are inadequate as they fail to effectively replace damaged cellular layers, leading to limited recovery and complications like graft rejection and neovascularization, with no effective means for reconstituting retinal pigment epithelium (RPE) cells.
Innovation Solution
The development of methods to derive RPE and RPE-like cells from human embryonic stem cells, which can be transplanted into the subretinal space using vitrectomy surgery, and the use of genetically modified cells to prevent neovascularization, allowing for the production of functional RPE cells and other eye tissue types to treat various conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RPE cells are transplanted to treat retinal degeneration, then vision restoration is achieved, but graft rejection occurs
Solution Approach 1:
The patent applies parameter changes by modifying the genetic parameters of RPE cells through gene therapy. Specifically, cells are modified to express anti-apoptotic genes (such as Bcl-2) or other therapeutic genes that prevent graft rejection and promote survival. This genetic modification changes the biological parameters of the transplanted cells, enabling them to resist host immune rejection while maintaining their function in restoring vision.
2Ease of manufacture
If conventional therapies are used for retinal degeneration, then treatment is provided, but effective replacement of damaged cellular layers is not achieved
Solution Approach 1:
The patent employs the copying principle by creating functional copies of healthy RPE cells through stem cell differentiation. Instead of using damaged host cells or donor tissue that may be rejected, the invention generates identical functional copies of healthy RPE cells from pluripotent stem cells. These copied cells are then transplanted to replace damaged cellular layers, achieving reliable regeneration without the limitations of conventional therapies.
Solution Approach 2:
The patent utilizes parameter changes by manipulating the differentiation parameters of stem cells to generate RPE cells with specific functional properties. Through controlled exposure to differentiation factors and cultural conditions, stem cells are directed to become functional RPE cells with restored photoreceptor support capabilities, enabling effective cellular layer replacement.
3Reliability
If RPE cells are transplanted to replace damaged layers, then vision function is restored, but neovascularization complications arise
Solution Approach 1:
The patent applies preliminary anti-action by pre-treating transplanted RPE cells with anti-angiogenic factors or gene modifications that prevent neovascularization before transplantation. Cells are engineered to express proteins that inhibit abnormal blood vessel formation, thereby preventing this harmful complication from occurring in the first place while still enabling vision restoration through functional RPE cell replacement.
Data Source
AI summary
This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.